Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with
coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). Despite the use …

Background Ticagrelor and prasugrel are third‐generation oral P2Y12 receptor antagonists
with rapid onset and pronounced platelet inhibition. However, higher overall bleeding rates …

Objectives: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes
in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF …

Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …

The aspirin–clopidogrel combination is the current gold standard antiplatelet regimen
following percutaneous coronary intervention and for the treatment of acute coronary …

Dual antiplatelet therapy using aspirin and a platelet P2Y12 receptor inhibitor is a
cornerstone therapy for acute coronary syndrome (ACS)[1]. Since clopidogrel has proved his …

Dual antiplatelet therapy consisting of one of the P2Y12 receptor inhibitors in conjunction
with aspirin is the mainstay of treatment for patients with acute coronary syndromes (ACS) …

Dual antiplatelet therapy (DAPT), or the combination of aspirin and an oral inhibitor of the
platelet P2Y12 receptor, is indicated in acute coronary syndromes (ACS) and after …

The current standard of antiplatelet therapy of patients after myocardial infarction includes
the P2Y 12 receptor antagonists clopidogrel, prasugrel or ticagrelor. This study aimed to …